In a post on X (formerly Twitter), Neuralink described the trial as “an important first step towards restoring not only digital freedom but also physical freedom.” The study is named the CONVOY Study.
The announcement follows Neuralink’s recent statement that it plans to launch its first international clinical trial in Canada.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.